Auto-Immune Pancreatitis with Pseudo-Tumoral Mass Induced by Pembrolizumab in a Woman suffering from Metastatic Urothelial Carcinoma: Case Report and Literature survey
| Journal | Volume 88 - 2025 |
| Issue | Fasc.4 - Case reports |
| Author(s) | G. Bastens 1, N. Bletard 2, G. Matus 3, F. Jehaes 4, O. Plomteux 1, F. Renier 5, R. Materne 5, B. Bastens 1, C. Focan 3 |
| Full article |
 PAGES 371-374 VIEW FREE PDF |
| DOI | 10.51821/88.4.14217 |
|
Affiliations: (1) Gastroenterology Department, CHC MontLégia, Liège, Belgium
(2) Anatomopathology Department, CHC MontLégia, Liège, Belgium (3) Onco-Hematology Department, CHC MontLégia, Liège, Belgium (4) Digestive Surgery Department, CHC MontLégia, Liège, Belgium (5) Medical Imaging Department, CHC MontLégia, Liège, Belgium |
|
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but may induce rare immune-related adverse events including pancreatitis (ICI-PI-), which occurs in 2–4% of cases. Such ICI-PI may necessitate treatment discontinuation. We report the rare case of a 51-year-old female with Lynch syndrome treated with pembrolizumab for metastatic urothelial carcinoma. A pancreatic mass was identified during follow-up by PET/CT. Pathology from endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) could not exclude adenocarcinoma. Surgical resection revealed pathology consistent with type II autoimmune pancreatitis (AIP) in a case which represent by definition , a type III ICI-PI. We explore diagnostic criteria focusing on clinical, serological, histological as well as medical imaging features and management Keywords: immune checkpoint inhibitors (ICIs), pembrolizumab, pancreatitis, urothelial carcinoma. |
| The authors declare that they have no conflict of interest. |
|
© Acta Gastro-Enterologica Belgica. PMID 41493326 |